1. Home
  2. TMQ vs PHAT Comparison

TMQ vs PHAT Comparison

Compare TMQ & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trilogy Metals Inc.

TMQ

Trilogy Metals Inc.

SELL

Current Price

$1.83

Market Cap

579.8M

ML Signal

SELL

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

SELL

Current Price

$5.86

Market Cap

590.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TMQ
PHAT
Founded
2004
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
579.8M
590.6M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
TMQ
PHAT
Price
$1.83
$5.86
Analyst Decision
Buy
Strong Buy
Analyst Count
6
11
Target Price
$6.64
★ $20.05
AVG Volume (30 Days)
1.4M
★ 1.8M
Earning Date
10-02-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 42.72
EPS
★ N/A
N/A
Revenue
N/A
★ $175,110,000.00
Revenue This Year
N/A
$79.63
Revenue Next Year
N/A
$54.71
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 216.93
52 Week Low
$1.81
$5.02
52 Week High
$7.25
$18.31

Technical Indicators

Market Signals
Indicator
TMQ
PHAT
Relative Strength Index (RSI) 29.05 43.87
Support Level N/A $5.03
Resistance Level $2.35 $7.72
Average True Range (ATR) 0.14 0.56
MACD 0.00 0.09
Stochastic Oscillator 0.93 41.07

Price Performance

Historical Comparison
TMQ
PHAT

About TMQ Trilogy Metals Inc.

Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: